APVO451 / Aptevo Therap - LARVOL DELTA

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors (ACCESS Newswire) - "Key Findings from the Presentation: Local Activation in the Tumor: APVO451 triggered T-cell and APC activation only when bound to the target nectin-4, suggesting the potential for strong immune activity without systemic over-activation resulting in a potentially favorable safety profile; Dual Immune Re-Activation: The molecule stimulated the effector functions of T-cells and restored APC function - two arms of the immune system that cause treatments to often fail in solid tumors due to the tumors' ability to suppress the immune system; Activity Under Suppressive Conditions: In cultured tumor models designed to mimic tumor suppression, APVO451 eliminated nectin-4-positive tumor cells more effectively than a standard CD3 T-cell engager potentially demonstrating the ability of APVO451 to overcome a suppressive tumor microenvironment."

Preclinical • Breast Cancer • Pancreatic Cancer • Urothelial Cancer

A breakthrough in fighting solid tumors with a novel trispecific targeting Nectin-4, CD3 and CD40 to overcome the immunosuppressive tumor microenvironment (SITC 2025) - "The CD40-directed arm of APVO451 led to the induction of IL-12 secretion and upregulation of CD80/CD86, which may play an important role in overcoming the suppression of MDSC in the TME. This trispecific antibody is a promising anti-cancer therapeutic for the treatment of various solid tumors with suppressive TME via costimulation of APC while simultaneously providing signal 1 to tumor-infiltrating T cells."

Biomarker • Trispecific • Tumor microenvironment • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CD40 • CD80 • CD86 • IL12A • NECTIN4

Society of Immunotherapy in Cancer (SITC) 2025 - 40th Anniversary Annual Meeting (ACCESS Newswire) - "Aptevo's R&D Team will present a poster highlighting a novel trispecific targeting Nectin-4, CD3 and CD40 to overcome the immunosuppressive the tumor microenvironment."

Preclinical • Oncology

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules (ACCESS Newswire) - "Aptevo Therapeutics Inc...announced expansion of its anti-cancer pipeline with the filing of two provisional patents for trispecific candidates, APVO452 and APVO451 for prostate cancer and multiple, additional solid tumor types with significant unmet needs."

New molecule • Prostate Cancer • Solid Tumor